Author Title Type [ Year(Desc)]
Filters: Author is de Lima, Marcos  [Clear All Filters]
Dharmavaram G, Cao S, Sundaram S, Ayyapan S, Boughan K, Gallogly M, Malek E, Metheny L, Tomlinson B, Otegbeye F, et al. Aggressive Lymphoma Subtype Is A Risk Factor for Venous Thrombosis. Development of Lymphoma - Specific Venous Thrombosis Prediction Models. Am J Hematol. 2020.
Bejanyan N, Zhang M, Bo-Subait K, Brunstein C, Wang H, Warlick ED, Giralt S, Nishihori T, Martino R, Passweg J, et al. Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myeloid Leukemia and Myelodysplastic Syndromes with Low/Intermediate, but not High Disease Risk Index: A CIBMTR Study: Superior DFS with MAC comp. Biol Blood Marrow Transplant. 2020.
Oran B, de Lima M, Garcia-Manero G, Thall PF, Lin R, Popat U, Alousi AM, Hosing C, Giralt S, Rondon G, et al. A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients. Blood Adv. 2020;4(21):5580-5588.
Ueda M, Stefan T, Stetson L, Ignatz-Hoover JJ, Tomlinson B, Creger RJ, Cooper B, Lazarus HM, de Lima M, Wald DN, et al. Phase I Trial of Lithium and Tretinoin for Treatment of Relapsed and Refractory Non-promyelocytic Acute Myeloid Leukemia. Front Oncol. 2020;10:327.
Zhou Z, Nath R, Cerny J, Wang H-L, Zhang M-J, Abdel-Azim H, Agrawal V, Ahmed G, A Al-Homsi S, Aljurf M, et al. Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. Blood Adv. 2020;4(13):3180-3190.
Anandan A, Kolk M, Ferrari N, Copley M, Driscoll J, Caimi P, Rashidi A, de Lima M, Malek E. Serum Electrolyte Dynamics in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation. Nephrology (Carlton). 2020.
Guha A, Dey AKumar, Al-Kindi S, P Miller E, Ghosh A, Banerjee A, Lopez-Mattei J, Desai NR, Patel B, Oliveira GH, et al. Socio-economic Burden of Myocardial Infarction among Cancer Patients. Am J Cardiol. 2020.